Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3164 - PI3K/RICTOR-mTORC2 axis as a driver of prognosis and potential druggable target in squamous cell lung carcinoma (SqCLC).


11 Sep 2017


Poster display session


Translational Research;  Thoracic Malignancies


Sara Pilotto


Annals of Oncology (2017) 28 (suppl_5): v573-v594. 10.1093/annonc/mdx390


S. Pilotto1, M. Simbolo2, A. Gkountakos3, C. Vicentini2, I. Sperduti4, V. Ludovini5, R. Chiari5, S. Novello6, M. Milella7, A. Mafficini2, L. Carbognin1, E. Caregnato1, A. Santo1, M. Infante8, M. Brunelli3, V. Corbo2, A. Scarpa2, G. Tortora1, E. Bria1

Author affiliations

  • 1 Medical Oncology, University of Verona, 37134 - Verona/IT
  • 2 Arc-net Centre For Applied Research On Cancer, University and Hospital Trust of Verona, Verona/IT
  • 3 Department Of Pathology And Diagnostics,, University and Hospital Trust of Verona, Verona/IT
  • 4 Biostatistics, Regina Elena National Cancer Institute, Rome/IT
  • 5 Medical Oncology, Ospedale S. Maria della Misericordia, 06156 - Perugia/IT
  • 6 Department Of Oncology, University of Turin, Torino/IT
  • 7 Medical Oncology, Regina Elena National Cancer Institute, Rome/IT
  • 8 Thoracic Surgery, University of Verona, 37134 - Verona/IT


Abstract 3164


We built a risk classification model for resected SqCLC (R-SqCLC) by combining clinicopathological predictors to discriminate patients' (pts) prognosis (Pilotto JTO 2015), we externally validated this model in a pts’ cohort of > 1,300 R-SqCLC (Bria WCLC 2016) and we performed an integrated multi-platforms genome analysis of prognostic outliers to identify potentially druggable modulators as the PI3K/RICTOR-mTORC2 axis (Pilotto WCLC 2016). Here, we validate our molecular findings and we enhance our rationale with in vitro studies.


Next Generation Sequencing (NGS) analysis of somatic mutations (SM) and copy number alterations (SCNA) was performed (Ion AmpliSeq Lung & Colon Cancer Panel: 22 genes, a SqCLC customized targeted NGS panel: 20 genes, the commercial Ion AmpliSeq Comprehensive Cancer Panel: 409 genes). In vitro experiments were performed using the SqCLC cell line H-1703 (Rictor amplified-6 copies). PF-05212384 [PI3K/mTOR inhibitor (inh)], AZD2014 (mTORC1/2 inh), MK-2206 (panAkt inh), everolimus (mTOR inh) and chemotherapeutic drugs (Docetaxel, Gemcitabine) were tested. Cell viability was assessed by crystal violet assay and the half maximal inhibitory concentration (IC50) was estimated to evaluate drug efficacy.


Main results of overall 97 pts (Training/Validation: 60/37) are presented in the Table.Table:


GeneTraining Set [%]Validation Set [%]
SMTP5353 [88.3]27 [72.9]
TIE14 [6.7]2 [5.4]
PTEN6 [10]4 [10.8]
PIK3CA3 [5]3 [8.1]
SCNA GainsRICTOR13 [35.1]14 [23.3]
PIK3CA17 [45.9]26 [43.3]
FRS28 [21.6]7 [11.7]
FGFR114 [37.8]18 [30]
SCNA LossesPTEN5 [13.5]19 [31.7]
TSC28 [21.6]7 [11.7]

The in vitro results support a significant inhibition of H-1703 cells proliferation by Gemcitabine, Docetaxel, PF-05212384, MK-2206 and AZD2014 with IC50 values of 0.4 nM, 0.45 nM, 10 nM, 66 nM, 110 nM, respectively. Everolimus was not effective.


Our multi-step genomic analysis performed in almost 100 R-SqCLC pts allowed us to identify altered pathways with a biological impact in SqCLC oncogenesis, as the PI3K/RICTOR-mTORC2 axis. Moreover, our in vitro results justify pursuing mTOR inhibition, focusing on mTORC2 complex, in RICTOR-aberrant tumors.

Clinical trial identification

Not Applicable

Legal entity responsible for the study

Emilio Bria


My First AIRC (Associazione Italiana per la Ricerca sul Cancro) Grant (MFAG) project no. 14282. Young Investigational Award of the International Association for the Study of Lung Cancer (IASLC) 2015


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.